Setmelanotide Phase 3 Trial Hits Primary Endpoint with 16.4% BMI Reduction; PDUFA Date Set for March 20
RYTM has more than doubled off its 52-week low of $45.905.
Summary
Rhythm Pharmaceuticals announced additional positive Phase 3 data for Setmelanotide in patients with acquired hypothalamic obesity, achieving the primary endpoint with a significant 16.4% BMI reduction. Concurrently, the company confirmed a PDUFA goal date of March 20, 2026, for the drug. This news is highly material as positive Phase 3 results, especially hitting the primary endpoint with a strong clinical outcome, significantly de-risk the drug's regulatory path and enhance its commercial prospects. The confirmed PDUFA date provides a clear, near-term catalyst for a potential FDA approval decision, which is expected to drive substantial stock movement. Traders will now closely monitor the FDA's decision by the specified PDUFA date.
At the time of this announcement, RYTM was trading at $92.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $45.91 to $122.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.